Application of a newly-developed cynomolgus macaque BiTE-mediated cytotoxic T-lymphocyte activity assay to various immunomodulatory agents in vitro

References

• Allison A, Eugui E. 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Bar-Or A. 2014. Teriflunomide (Aubagio(R)) for the treatment of multiple sclerosis. Exp Neurol. 262:57–65.
   PubMed Web of Science ®Google Scholar
• Barnes P. 2006. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 148(3):245–254.
   PubMed Web of Science ®Google Scholar
• Benson J, Sachs C, Treacy G, Zhou H, Pendley C, Brodmerkel C, Shankar G, Mascelli M. 2011. Therapeutic targeting of the IL-12/23 pathways: Generation and characterization of ustekinumab. Nat Biotechnol. 29(7):615–624.
   PubMed Web of Science ®Google Scholar
• Bottcher J, Schanz O, Garbers C, Zaremba A, Hegenbarth S, Kurts C, Beyer M, Schultze J, Kastenmuller W, Rose-John S, et al. 2014. IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function. Cell Rep. 8(5):1318–1327.
   PubMed Web of Science ®Google Scholar
• Brehm M, Daniels K, Welsh R. 2005. Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol. 175(8):5043–5049.
   PubMed Web of Science ®Google Scholar
• Buurman D, Blokzijl T, Festen E, Pham B, Faber K, Brouwer E, Dijkstra G. 2018. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNFα biologicals and an Infliximab-biosimilar. PLOS One. 13(12):e0208922.
   PubMed Web of Science ®Google Scholar
• Clarke A, Poulton L, Wai H, Walker S, Victor S, Domagala T, Mraovic D, Butt D, Shewmaker N, Jennings P, et al. 2010. A novel class of anti-IL-12p40 antibodies: Potent neutralization via inhibition of IL-12-IL-12Rβ2 and IL-23-IL-23R. MAbs. 2(5):539–549.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D'Haens G, Geboes K, van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy S, Targan S, et al. 2001. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 15(4):463–473.
   PubMed Web of Science ®Google Scholar
• de Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, Wiedermann U, Kundi M, Zlabinger G, Grabmeier-Pfistershammer K, et al. 2019. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. 9(1):11472.
   PubMedGoogle Scholar
• Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B, et al. 2017. A CD80-biased CTLA4-Ig fusion protein with superior in vivo efficacy by simultaneous engineering of affinity, selectivity, stability, and FcRn Binding. J Immunol. 198(1):528–537.
   PubMed Web of Science ®Google Scholar
• Dumont F, Su Q. 1996. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58(5):373–395.
   PubMed Web of Science ®Google Scholar
• Dunn G, Old L, Schreiber R. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21(2):137–148.
   PubMed Web of Science ®Google Scholar
• Elli E, Barate C, Mendicino F, Palandri F, Palumbo G. 2019. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 9:1186.
   PubMed Web of Science ®Google Scholar
• Fox R, Herrmann M, Frangou C, Wahl G, Morris R, Strand V, Kirschbaum B. 1999. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 93(3):198–208.
   PubMed Web of Science ®Google Scholar
• Frank B, Wei Y, Kim K, Guerrero A, Lebrec H, Balazs M, Wang X. 2018. Development of a BiTE®-mediated CD8+ cytotoxic T-lymphocyte activity assay to assess immunomodulatory potential of drug candidates in Cynomolgus macaque. J Immunotoxicol. 15(1):119–125.
   PubMed Web of Science ®Google Scholar
• Herrero-Beaumont G, Martinez Calatrava M, Castaneda S. 2012. Abatacept mechanism of action: Concordance with its clinical profile. Reumatol Clin. 8(2):78–83.
   PubMedGoogle Scholar
• Hodge J, Kawabata T, Krishnaswami S, Clark J, Telliez J, Dowty M, Menon S, Lamba M, Zwillich S. 2016. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 34(2):318–328.
   PubMed Web of Science ®Google Scholar
• ICH. 2005. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Immunotoxicity Studies for Human Pharmaceuticals S8.
   Google Scholar
• Jacobson P, Uberti J, Davis W, Ratanatharathorn V. 1998. Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 22(3):217–225.
   PubMed Web of Science ®Google Scholar
• Lebrec H, Brennan F, Haggerty H, Herzyk D, Kamperschroer C, Maier C, Ponce R, Preston B, Weinstock D, Mellon R. 2016. HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach. Regul Toxicol Pharmacol. 75:72–80.
   PubMed Web of Science ®Google Scholar
• Leger O, Yednock T, Tanner L, Horner H, Hines D, Keen S, Saldanha J, Jones S, Fritz L, Bendig M. 1997. Humanization of mouse antibody against human α4 integrin: Potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 8(1):3–16.
   PubMedGoogle Scholar
• Li J, Piskol R, Ybarra R, Chen Y, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, et al. 2019a. CD3 bi-specific antibody-induced cytokine release is dispensable for cytotoxic T-cell activity. Sci Transl Med. 11:eaax8861.
   PubMed Web of Science ®Google Scholar
• Li J, Stagg N, Johnston J, Harris M, Menzies S, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, et al. 2017. Membrane-proximal epitope facilitates efficient T-cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 31(3):383–395.
   PubMed Web of Science ®Google Scholar
• Li X, Roy A, Murthy B. 2019b. Population pharmacokinetics and exposure-response relationship of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis. J Clin Pharmacol. 59(2):245–257.
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, et al. 2010. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA. 107(28):12605–12610.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo C, Cinamon G, Lesneski M, Xu Y, Brinkmann V, Allende M, Proia R, Cyster J. 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427(6972):355–360.
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. 2005. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 5(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• Moller A, Emling F, Blohm D, Schlick E, Schollmeier K. 1990. Monoclonal antibodies to human TNFα: In vitro and in vivo application. Cytokine. 2(3):162–169.
   PubMedGoogle Scholar
• Narita M, Nishizawa Y, Iwaya S, Oiwa E, Iwabuchi M, Uchiyama T, Matsuyama A, Masuko M, Takahashi M. 2014. Ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T-lymphocytes. Int Arch Allergy Immunol. 165(1):52–60.
   PubMed Web of Science ®Google Scholar
• Ogata A, Hirano T, Hishitani Y, Tanaka T. 2012. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 5:27–42.
   PubMedGoogle Scholar
• Ross S, Sherman M, McElroy P, Lofgren J, Moody G, Baeuerle P, Coxon A, Arvedson T. 2017. Bi-specific T-cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing. PLOS One. 12(8):e0183390.
   PubMed Web of Science ®Google Scholar
• Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, et al. 2020. Combination of T-cell bi-specific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity. Front Oncol. 10:575737.
   PubMedGoogle Scholar
• Schafer P. 2012. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Schurich A, Pallett L, Lubowiecki M, Singh H, Gill U, Kennedy P, Nastouli E, Tanwar S, Rosenberg W, Maini M. 2013. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLOS Pathog. 9(3):e1003208.
   PubMed Web of Science ®Google Scholar
• Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, Chan A, Ziemssen T. 2016. New insights into pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation. 13:164.
   PubMedGoogle Scholar
• Shefrin A, Goldman R. 2009. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. Can Fam Physician. 55(7):704–706.
   PubMed Web of Science ®Google Scholar
• Stuve O, Bennett J. 2007. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 13(1):79–95.
   PubMedGoogle Scholar
• Thomson A, Bonham C, Zeevi A. 1995. Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms. Ther Drug Monit. 17(6):584–591.
   PubMed Web of Science ®Google Scholar
• Tsakok T, Wilson N, Dand N, Loeff F, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing J, et al. 2019. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 155(11):1235–1243.
   PubMed Web of Science ®Google Scholar
• Tsuda K, Yamanaka K, Kondo M, Matsubara K, Sasaki R, Tomimoto H, Gabazza E, Mizutani H. 2012. Ustekinumab improves psoriasis without altering T-cell cytokine production, differentiation, and T-cell receptor repertoire diversity. PLOS One. 7(12):e51819.
   PubMed Web of Science ®Google Scholar
• Volpi C, Orabona C, Macchiarulo A, Bianchi R, Puccetti P, Grohmann U. 2019. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opin Drug Discov. 14(11):1199–1212.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium K, Han M, Wang X, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. 2014. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2(9):846–856.
   PubMed Web of Science ®Google Scholar
• Weisman M, Moreland L, Furst D, Weinblatt M, Keystone E, Paulus H, Teoh L, Velagapudi R, Noertersheuser P, Granneman G, et al. 2003. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-TNFα monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: Pilot study. Clin Ther. 25(6):1700–1721.
   PubMed Web of Science ®Google Scholar
• Wust S, van den Brandt J, Tischner D, Kleiman A, Tuckermann J, Gold R, Luhder F, Reichardt H. 2008. Peripheral T-cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol. 180(12):8434–8443.
   PubMed Web of Science ®Google Scholar